---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-03T22:11:51.733736'
end_time: '2025-12-03T22:20:01.421498'
duration_seconds: 489.69
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: CHAMP1
  gene_symbol: CHAMP1
  uniprot_accession: Q96JM3
  protein_description: 'RecName: Full=Chromosome alignment-maintaining phosphoprotein
    1; AltName: Full=Zinc finger protein 828;'
  gene_info: Name=CHAMP1; Synonyms=C13orf8, CAMP, CHAMP, KIAA1802, ZNF828;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: CAMP. (IPR039330); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type. (IPR013087)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 18
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96JM3
- **Protein Description:** RecName: Full=Chromosome alignment-maintaining phosphoprotein 1; AltName: Full=Zinc finger protein 828;
- **Gene Information:** Name=CHAMP1; Synonyms=C13orf8, CAMP, CHAMP, KIAA1802, ZNF828;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** CAMP. (IPR039330); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type. (IPR013087)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CHAMP1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CHAMP1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CHAMP1** (gene ID: CHAMP1, UniProt: Q96JM3) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96JM3
- **Protein Description:** RecName: Full=Chromosome alignment-maintaining phosphoprotein 1; AltName: Full=Zinc finger protein 828;
- **Gene Information:** Name=CHAMP1; Synonyms=C13orf8, CAMP, CHAMP, KIAA1802, ZNF828;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** CAMP. (IPR039330); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type. (IPR013087)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CHAMP1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CHAMP1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CHAMP1** (gene ID: CHAMP1, UniProt: Q96JM3) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan (concise)
1) Verify identity of CHAMP1 (Q96JM3) and domain architecture. 2) Synthesize 2023–2024 literature on molecular function, localization, interactors, and mechanisms in mitosis/DNA repair. 3) Summarize disease relevance with recent patient- and cell-based evidence, including mechanism of pathogenic variants. 4) Highlight real-world applications (diagnostics; potential therapy-relevant biology). 5) Provide a referenced research report with URLs and dates.

Verification of target identity and scope
CHAMP1 here refers to the human zinc finger protein “Chromosome alignment-maintaining phosphoprotein 1” (UniProt Q96JM3), also known as ZNF828/C13orf8. It is an ~812 aa nuclear protein with C2H2-type zinc fingers and internal motifs (WK, SPE, FPE). This matches the UniProt description and recent reviews/phenotyping work that place CHAMP1 at chromatin, kinetochores, and spindle microtubules and interacting with HP1 and POGZ. No conflicting gene with the same symbol was identified in the human literature cited below (levy2023prospectivephenotypingof pages 1-2).

Key concepts and definitions (current understanding)
- Molecular function and domains: CHAMP1 is a chromatin- and mitosis-associated zinc finger protein that contributes to stable kinetochore–microtubule attachment and proper chromosome alignment at metaphase. It contains N- and C-terminal C2H2 ZNF regions and a central WK motif that binds REV7/MAD2L2; an FPE motif supports kinetochore/spindle localization. It forms a complex with POGZ and HP1α in heterochromatin. It also modulates DNA double-strand break (DSB) repair, promoting homologous recombination (HR) at least partly by functionally antagonizing the REV7/Shieldin axis and facilitating end resection/BRCA1 functions (levy2023prospectivephenotypingof pages 1-2, caugherty2024thegenomicsof pages 8-13, caugherty2024thegenomicsofb pages 8-13, li2025champ1complexdirects pages 1-5, yoshizaki2024champ1prematuretermination pages 1-2).
- Cellular localization: Interphase—chromatin/heterochromatin; Mitosis—chromosomes, spindle fibers, and kinetochores. CHAMP1 co-localizes with γH2AX at DSB sites following genotoxic stress (caugherty2024thegenomicsof pages 8-13, caugherty2024thegenomicsofb pages 8-13).

Recent developments and latest research (priority 2023–2024)
- Pathogenic mechanism in patients: A 2024 Scientific Reports study demonstrated that premature termination codon (PTC) mutations identified in individuals with intellectual disability generate truncated CHAMP1 proteins and cause HR defects through a haploinsufficiency mechanism; missense variants retained HR function in the tested assays. Heterozygous CHAMP1 depletion also impaired HR, supporting dosage sensitivity (Scientific Reports, 12/2024; https://doi.org/10.1038/s41598-024-83435-y) (yoshizaki2024champ1prematuretermination pages 1-2).
- Heterochromatin and HDR: A 2024 preprint from the D’Andrea/Greenberg group proposed a CHAMP1–POGZ–HP1α heterochromatin complex that recruits SETDB1, promotes H3K9me3 deposition, heterochromatin clustering (including centromeres and ALT telomeres), and enhances HR/HDR specifically within heterochromatin. Patient lymphocytes with CHAMP1 syndrome showed defective heterochromatin clustering and impaired local DSB repair (bioRxiv posted 9/25/2024; https://doi.org/10.1101/2024.09.23.614480) (li2025champ1complexdirects pages 1-5).
- Clinical evidence for mechanism: A 2023 prospective phenotyping study contrasted individuals with coding CHAMP1 mutations versus 13q34 deletions including CHAMP1. The mutation group had more severe adaptive impairments, suggesting whole-gene deletions act via haploinsufficiency, whereas coding PTC mutations may have additional dominant-negative or gain-of-function effects clinically; nevertheless, cellular HR studies (above) highlight haploinsufficiency for HR function of CHAMP1 PTC alleles (Human Genetics, online 7/16/2023; https://doi.org/10.1007/s00439-023-02578-6) (levy2023prospectivephenotypingof pages 1-2).

Mechanisms and pathways (precise roles, localization, interactions)
- Mitosis/kinetochores: Loss of CHAMP1 in human cells causes metaphase misalignment, prolonged mitosis with active spindle-assembly checkpoint markers (MAD2L1-positive kinetochores), spindle axis defects, multipolar spindles, and reduced sister-kinetochore tension. The FPE region supports kinetochore/spindle localization and rescue of alignment defects (caugherty2024thegenomicsof pages 8-13, caugherty2024thegenomicsofb pages 8-13).
- DNA repair pathway choice and REV7: CHAMP1 binds REV7 via the WK motif and competes with Shieldin (e.g., SHLD3) for REV7, promoting HR over NHEJ; CHAMP1 loss decreases HR, increases genotoxic sensitivity, and—importantly—REV7-binding–defective CHAMP1 fails to restore PARP inhibitor resistance in functional assays, linking CHAMP1 to PARPi response biology (bioRxiv 10/2021; https://doi.org/10.1101/2021.10.04.463067; summarized in 2024 synthesis excerpts) (caugherty2024thegenomicsof pages 8-13, caugherty2024thegenomicsofb pages 8-13).
- Heterochromatin and SETDB1: The 2024 preprint places CHAMP1 in a POGZ–HP1α complex that targets heterochromatin, recruits SETDB1, and enhances HDR in chromatin contexts where HR is challenging (centromeres/telomeres, ALT telomeres) (bioRxiv 9/25/2024; https://doi.org/10.1101/2024.09.23.614480) (li2025champ1complexdirects pages 1-5).

Current applications and real-world implementations
- Diagnostics and variant interpretation: Exome/panel sequencing identifies predominantly de novo truncating (PTC) variants in CHAMP1 in individuals with neurodevelopmental disorders. The 2023 prospective study emphasized that coding PTC variants may present with more severe phenotypes than 13q34 deletions, urging caution in therapeutic strategies and supporting dedicated variant interpretation frameworks that consider potential NMD escape and truncated protein expression (Human Genetics, 2023; https://doi.org/10.1007/s00439-023-02578-6) (levy2023prospectivephenotypingof pages 1-2).
- Therapy-relevant biology: Functional studies connecting CHAMP1 to HR versus NHEJ suggest CHAMP1 status could influence PARP inhibitor sensitivity in tumors: CHAMP1 presence and REV7 binding promote HR and can confer PARPi resistance, while CHAMP1 loss suggests potential PARPi vulnerability. These are preclinical insights requiring disease- and context-specific validation (bioRxiv 10/2021; https://doi.org/10.1101/2021.10.04.463067; bioRxiv 9/25/2024; https://doi.org/10.1101/2024.09.23.614480) (caugherty2024thegenomicsof pages 8-13, li2025champ1complexdirects pages 1-5).

Expert opinions and analysis from authoritative sources
- 2023 Human Genetics prospective phenotyping and review emphasizes that: (i) CHAMP1 is single-exon, nuclear, with C2H2 ZNFs and internal motifs (WK/FPE); (ii) interacts with POGZ and HP1 via the C-terminal ZNF; (iii) patient PTC transcripts may escape NMD and produce truncated proteins; (iv) clinical severity differences between coding mutations and gene deletions raise the possibility that coding PTCs act beyond simple haploinsufficiency, although cellular HR assays (2024 Sci Rep) support haploinsufficiency for HR function (Human Genetics, 7/16/2023; https://doi.org/10.1007/s00439-023-02578-6) (levy2023prospectivephenotypingof pages 1-2, yoshizaki2024champ1prematuretermination pages 1-2).
- 2024 preprint integrates heterochromatin biology and DNA repair, positioning CHAMP1–POGZ–HP1α as a chromatin module that promotes HDR, a conceptual advance connecting mitotic/kinetochore roles of CHAMP1 to interphase chromatin organization and DSB repair in heterochromatin (bioRxiv, 9/25/2024; https://doi.org/10.1101/2024.09.23.614480) (li2025champ1complexdirects pages 1-5).

Relevant statistics and data from recent studies
- Variant classes: Predominance of de novo truncating (PTC) variants among reported pathogenic alleles; patient cells with PTC mutations express truncated CHAMP1 and exhibit HR defects (Scientific Reports, 12/2024; https://doi.org/10.1038/s41598-024-83435-y) (yoshizaki2024champ1prematuretermination pages 1-2).
- Phenotype severity by variant type: Prospective comparison indicated significantly lower adaptive functioning across domains in the mutation (coding PTC) group relative to individuals with larger 13q34 deletions including CHAMP1 (Human Genetics, 2023; https://doi.org/10.1007/s00439-023-02578-6) (levy2023prospectivephenotypingof pages 1-2).
- Cell-based functional readouts: CHAMP1 depletion reduces HR reporter activity, increases sensitivity to CPT, IR, and other genotoxic agents; a REV7-binding–defective CHAMP1 mutant fails to restore HR-associated PARPi resistance, quantifying CHAMP1’s contribution to HR competence in standard assays (bioRxiv 10/2021; https://doi.org/10.1101/2021.10.04.463067; synthesis excerpts 2024) (caugherty2024thegenomicsof pages 8-13, caugherty2024thegenomicsofb pages 8-13).

Mechanistic synthesis: haploinsufficiency vs dominant-negative
- Cellular genetics/biochemistry: The 2024 patient-cell and depletion data strongly support haploinsufficiency for CHAMP1’s HR function, with missense variants largely retaining HR activity (Scientific Reports, 12/2024; https://doi.org/10.1038/s41598-024-83435-y) (yoshizaki2024champ1prematuretermination pages 1-2).
- Clinical phenotyping: The 2023 study’s more severe mutation-group phenotype than deletion-group suggests that some coding PTC variants might exert effects beyond simple loss of function (e.g., dominant-negative or gain-of-function), potentially due to truncated proteins escaping NMD and mislocalizing or failing to bind POGZ/HP1 properly (Human Genetics, 7/16/2023; https://doi.org/10.1007/s00439-023-02578-6) (levy2023prospectivephenotypingof pages 1-2).
- Emerging view: Together, data indicate the HR function is dosage sensitive (haploinsufficient), but clinical severity may be influenced by allele-specific properties of truncated proteins. This has implications for therapeutic design (e.g., gene replacement vs allele-specific strategies) (levy2023prospectivephenotypingof pages 1-2, yoshizaki2024champ1prematuretermination pages 1-2).

Detailed evidence summary (embed)
|Concept / Topic|Key findings (1–2 sentences)|Mechanistic / Structural notes (domains, motifs)|Cellular localization / context|Interactors / complex|Disease / clinical relevance|Year|Source (URL)|Context ID|
|---|---|---|---|---|---|---:|---|---|
|Identity & domains|CHAMP1 is an ~812 aa zinc-finger protein with multiple C2H2 ZNF motifs and internal repeat motifs (WK, SPE, FPE); encoded by a single exon in humans.|C- and N-terminal C2H2 ZNFs mediate protein interactions; WK motif binds REV7; FPE motif implicated in spindle/kinetochore localization.|Chromatin in interphase; chromosomes, spindle fibers and kinetochores during mitosis.|POGZ, HP1α, REV7 (MAD2L2); part of a CHAMP1–POGZ–HP1 complex.|Monogenic neurodevelopmental disorder (CHAMP1-related NDD/MRD40); mutations disrupt interactions.|2023|https://doi.org/10.1007/s00439-023-02578-6| (levy2023prospectivephenotypingof pages 1-2, caugherty2024thegenomicsofb pages 4-8) |
|Mitosis / kinetochore function|Required for accurate metaphase chromosome alignment and stable kinetochore–microtubule attachments; loss causes misalignment, prolonged mitosis, spindle defects and SAC activation.|FPE region required to rescue alignment defects; loss shortens inter-kinetochore distance and perturbs MAD2L2 localization.|Localizes to kinetochores and spindle during mitosis; affects sister-kinetochore tension.|MAD2L2 (REV7) involvement; functional linkage to core kinetochore machinery.|Defective mitosis/segregation likely contributes to neurodevelopmental phenotypes.|2024 (synthesis of primary data)|n/a| (caugherty2024thegenomicsof pages 8-13, levy2023prospectivephenotypingof pages 1-2) |
|DNA damage response (HR vs NHEJ via REV7/Shieldin)|CHAMP1 binds REV7 and sequesters it from Shieldin, promoting end resection and homologous recombination (HR); CHAMP1 loss reduces HR and increases reliance on NHEJ.|WK motif (e.g., W334/K335) mediates REV7 binding; C-terminal region is necessary/sufficient for HR activity.|CHAMP1 localizes to DSB sites (co-localizes with γH2AX); depletion increases sensitivity to genotoxic agents.|REV7 (MAD2L2), Shieldin components (SHLD3), BRCA1, POGZ, HP1.|Altered CHAMP1 levels affect genomic stability, HR proficiency, and can modulate PARP inhibitor sensitivity/resistance.|2021–2025|https://doi.org/10.1101/2021.10.04.463067, https://doi.org/10.1038/s41598-024-83435-y, https://doi.org/10.1101/2024.09.23.614480| (caugherty2024thegenomicsof pages 8-13, yoshizaki2024champ1prematuretermination pages 1-2, li2025champ1complexdirects pages 1-5) |
|Heterochromatin & SETDB1 (centromeres/telomeres)|CHAMP1–POGZ–HP1α complex promotes heterochromatin assembly (H3K9me3 deposition), heterochromatin clustering at centromeres and ALT telomeres, and enhances HDR in heterochromatin.|Complex recruits SETDB1 to heterochromatin; binds H3K9me3-enriched regions.|Enriched at pericentromeric heterochromatin and telomeric heterochromatin (including ALT telomeres).|POGZ, HP1α, SETDB1, LEDGF-associated factors.|Patient cells show defective heterochromatin clustering and impaired local DSB repair in CHAMP1 syndrome.|2024–25|https://doi.org/10.1101/2024.09.23.614480| (li2025champ1complexdirects pages 1-5, caugherty2024thegenomicsof pages 13-17) |
|Haploinsufficiency vs dominant-negative debate|Majority of reported pathogenic variants are premature termination codons (PTCs); evidence is mixed: PTCs often produce truncated proteins detectable in patient cells and can cause HR defects via haploinsufficiency, but clinical comparisons suggest coding PTCs may act more severely than whole-gene deletions (possible dominant-negative/gain-of-function).|PTC transcripts may escape NMD leading to truncated protein presence; missense variants less clearly pathogenic for HR function.|N/A (mechanistic consequence depends on mutation type and cellular context).|Truncated proteins can lose C-terminal ZNF-mediated binding to POGZ/HP1 and REV7.|Impacts variant interpretation and therapeutic strategy decisions (e.g., gene replacement risks).|2023–24|https://doi.org/10.1007/s00439-023-02578-6; https://doi.org/10.1038/s41598-024-83435-y| (levy2023prospectivephenotypingof pages 1-2, yoshizaki2024champ1prematuretermination pages 1-2) |
|Phenotypic spectrum & statistics|Clinical features: global developmental delay, intellectual disability, severe speech impairment, hypotonia, microcephaly, ASD traits, seizures, GI issues; cohorts show variable expressivity.|Most pathogenic reports are de novo truncating variants; cohort comparison: Levy et al. (16 mutation carriers vs 8 deletion carriers) found worse adaptive function in mutation group; approximate detection rates: rare (~1 in 500 in some ID cohorts reported).|N/A (clinical phenotype summary).|N/A (phenotype manifests systemically with neurodevelopmental prominence).|CHAMP1-related NDD (MRD40/CHAND) with variable systemic involvement; some reports of epilepsy and rare leukemia case.|2016–24|https://doi.org/10.1007/s00439-023-02578-6; n/a| (levy2023prospectivephenotypingof pages 1-2, caugherty2024thegenomicsofb pages 13-17) |
|Model organisms / functional models|Mouse homozygous knockout is perinatal lethal (on C57BL/6J) with increased cortical mitotic cells and delayed neuronal differentiation; heterozygotes display mild behavioral deficits.|KO recapitulates mitotic defects and neuronal differentiation delays; supports role in neurodevelopment.|Embryonic brain (neural progenitors) showed increased mitotic index and transcriptomic changes in neurodevelopment pathways.|N/A (model-system interactions mirror human partners)|Phenotypes in mice align with human neurodevelopmental features and support pathogenicity of loss-of-function.|2022|n/a| (caugherty2024thegenomicsofb pages 13-17) |
|Therapeutic implications & diagnostics|CHAMP1 status modulates HR and can alter PARP inhibitor sensitivity: overexpression can confer PARPi resistance by promoting HR; CHAMP1 loss may sensitize tumors to PARPi; diagnostic sequencing identifies truncating de novo variants.|REV7-binding is required for CHAMP1-dependent PARPi resistance (CHAMP1-2A mutant fails to restore resistance).|DSB repair context; tumor vs germline differences important.|REV7/Shieldin axis relevant to therapy response.|Potential utility in precision oncology (biomarker for PARPi response) and in clinical genetics for diagnosis and counseling.|2021–25|https://doi.org/10.1101/2021.10.04.463067; https://doi.org/10.1101/2024.09.23.614480| (caugherty2024thegenomicsof pages 8-13, li2025champ1complexdirects pages 1-5) |
|Diagnostic / variant-interpretation notes|Given possible NMD escape and truncated protein expression, interpret truncating CHAMP1 variants cautiously; compare sequence-level mutations vs 13q34 deletions for pathogenic mechanism.|Variant-type matters: PTCs (truncating) predominate among reported pathogenic alleles; missense variants less frequently reported as pathogenic for HR defects.|Consider functional assays (HR rescue, REV7-binding) for VUS interpretation.|Clinical testing by exome/wgs detects de novo variants; phenotype-driven interpretation recommended.|Clinical genetics: use mutation type and available functional data to infer mechanism before considering gene-targeted therapies.|2016–24|https://doi.org/10.1007/s00439-023-02578-6; n/a| (levy2023prospectivephenotypingof pages 1-2, caugherty2024thegenomicsofb pages 13-17) |


*Table: Concise, evidence-based table summarizing CHAMP1 (Q96JM3) molecular functions, domains, cellular localization, key interactors, clinical phenotypes, mechanistic debates, model data, and therapeutic implications with citations to the assembled 2023–2025 evidence (context IDs included).*

Conclusion
Human CHAMP1 (Q96JM3) is a nuclear zinc finger protein that operates at the interface of mitosis (kinetochore–microtubule attachment/chromosome alignment) and genome maintenance (HR promotion within heterochromatin via REV7/Shieldin antagonism and SETDB1-linked heterochromatin assembly). Recent 2023–2024 studies clarify that most pathogenic human variants are de novo truncating alleles; cellular data show haploinsufficiency for HR, whereas prospective clinical phenotyping suggests some coding mutations may act more severely than deletions, raising the possibility of additional dominant-negative/gain-of-function effects in vivo. These mechanistic insights inform diagnostics and raise testable hypotheses for therapy, including potential utility of CHAMP1 status as a biomarker of HR capacity and PARP inhibitor response in oncology, pending further validation (levy2023prospectivephenotypingof pages 1-2, caugherty2024thegenomicsof pages 8-13, caugherty2024thegenomicsofb pages 8-13, li2025champ1complexdirects pages 1-5, yoshizaki2024champ1prematuretermination pages 1-2).

References

1. (levy2023prospectivephenotypingof pages 1-2): Tess Levy, Thariana Pichardo, Hailey Silver, Bonnie Lerman, Jessica Zweifach, Danielle Halpern, Paige M. Siper, Alexander Kolevzon, and Joseph D. Buxbaum. Prospective phenotyping of champ1 disorder indicates that coding mutations may not act through haploinsufficiency. Human Genetics, 142:1385-1394, Jul 2023. URL: https://doi.org/10.1007/s00439-023-02578-6, doi:10.1007/s00439-023-02578-6. This article has 2 citations and is from a peer-reviewed journal.

2. (caugherty2024thegenomicsof pages 8-13): V Caugherty and Z Marie. The genomics of champ1: insights into their cell-type specificity and developmental trajectories. Unknown journal, 2024.

3. (caugherty2024thegenomicsofb pages 8-13): V Caugherty and Z Marie. The genomics of champ1: insights into their cell-type specificity and developmental trajectories. Unknown journal, 2024.

4. (li2025champ1complexdirects pages 1-5): Feng Li, Tianpeng Zhang, Aleem Syed, Amira Elbakry, Noella Holmer, Huy Nguyen, Sirisha Mukkavalli, Roger A. Greenberg, and Alan D. D’Andrea. Champ1 complex directs heterochromatin assembly and promotes homology-directed dna repair. Nature Communications, Sep 2025. URL: https://doi.org/10.1101/2024.09.23.614480, doi:10.1101/2024.09.23.614480. This article has 5 citations and is from a highest quality peer-reviewed journal.

5. (yoshizaki2024champ1prematuretermination pages 1-2): Yujiro Yoshizaki, Yunosuke Ouchi, Dicky Kurniawan, Eisuke Yumoto, Yuki Yoneyama, Faiza Ramadhani Rizqullah, Hiyori Sato, Mirjam Hanako Sarholz, Toyoaki Natsume, Masato T. Kanemaki, Masanori Ikeda, Ayako Ui, Kenji Iemura, and Kozo Tanaka. Champ1 premature termination codon mutations found in individuals with intellectual disability cause a homologous recombination defect through haploinsufficiency. Scientific Reports, Dec 2024. URL: https://doi.org/10.1038/s41598-024-83435-y, doi:10.1038/s41598-024-83435-y. This article has 1 citations and is from a peer-reviewed journal.

6. (caugherty2024thegenomicsofb pages 4-8): V Caugherty and Z Marie. The genomics of champ1: insights into their cell-type specificity and developmental trajectories. Unknown journal, 2024.

7. (caugherty2024thegenomicsof pages 13-17): V Caugherty and Z Marie. The genomics of champ1: insights into their cell-type specificity and developmental trajectories. Unknown journal, 2024.

8. (caugherty2024thegenomicsofb pages 13-17): V Caugherty and Z Marie. The genomics of champ1: insights into their cell-type specificity and developmental trajectories. Unknown journal, 2024.

## Citations

1. levy2023prospectivephenotypingof pages 1-2
2. caugherty2024thegenomicsofb pages 13-17
3. caugherty2024thegenomicsof pages 8-13
4. caugherty2024thegenomicsofb pages 8-13
5. caugherty2024thegenomicsofb pages 4-8
6. caugherty2024thegenomicsof pages 13-17
7. https://doi.org/10.1038/s41598-024-83435-y
8. https://doi.org/10.1101/2024.09.23.614480
9. https://doi.org/10.1007/s00439-023-02578-6
10. https://doi.org/10.1101/2021.10.04.463067;
11. https://doi.org/10.1007/s00439-023-02578-6|
12. https://doi.org/10.1101/2021.10.04.463067,
13. https://doi.org/10.1038/s41598-024-83435-y,
14. https://doi.org/10.1101/2024.09.23.614480|
15. https://doi.org/10.1007/s00439-023-02578-6;
16. https://doi.org/10.1038/s41598-024-83435-y|
17. https://doi.org/10.1007/s00439-023-02578-6,
18. https://doi.org/10.1101/2024.09.23.614480,